BridgeBio Pharma (BBIO) Other financing activities (2018 - 2026)

BridgeBio Pharma has reported Other financing activities for 9 years, with the latest figure at $5.5 million in Q1 2026.

• Quarterly Other financing activities rose 583.25% year-over-year to $5.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.8 million (up 2491.63% YoY) and the FY2025 annual result came in at $2.2 million, changed N/A from the prior year.
• Other financing activities climbed to $5.5 million in Q1 2026 per BBIO's latest filing, from -$12.4 million in the prior quarter.
• Over five years, Other financing activities peaked at $11.3 million in Q3 2025 and troughed at -$12.4 million in Q4 2025.
• A 5-year average of $585812.5 and a median of $668500.0 in 2024 frame the typical range for Other financing activities.
• The widest YoY moves for Other financing activities: up 37520.0% in 2025, down 1431.31% in 2025.
• Over 5 years, Other financing activities stood at $2.6 million in 2022, then slumped by 264.11% to -$4.2 million in 2023, then soared by 80.75% to -$808000.0 in 2024, then plunged by 1431.31% to -$12.4 million in 2025, then soared by 144.18% to $5.5 million in 2026.
• According to Business Quant data, Other financing activities over the past three periods registered $5.5 million, -$12.4 million, and $11.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.